A new peer-reviewed study published in the journal Diagnostics validates a multi-omic approach to detecting ovarian cancer, demonstrating that integrating lipidomic, metabolomic, and protein profiles offers higher clinical accuracy than single-modality tests. By analyzing 503 participants, researchers identified that ovarian cancer rewires multiple biological pathways simultaneously, providing the foundation for AOA Dx’s AKRIVIS GD diagnostic test.
Why Multi-Omics Outperforms Traditional Screening
Standard-of-care markers like CA125 and HE4 often struggle with specificity in symptomatic patients, frequently overlapping between early-stage ovarian cancer and benign conditions. According to the study, relying on a single class of biomarkers is insufficient for early detection because the disease signal is not binary.
The research, which utilized liquid chromatography-mass spectrometry and immunoassay, revealed that cancer creates distinct molecular signatures across three layers: lipids, metabolites, and proteins. Integrating these layers allows clinicians to view biological connections—such as energy metabolism and immune signaling—that individual tests simply miss. This “cross-omic network” explains why patients with borderline tumors or benign conditions often show molecular profiles falling between those of healthy individuals and those with malignant specimens.
Did you know?
Research suggests that ovarian cancer does not present as a simple “on/off” switch. Instead, it exists on a biological continuum, where molecular signatures shift gradually from benign to malignant states.
The Future of Diagnostic Adoption
The shift toward multi-omic diagnostics is gaining momentum in the investment community. Data presented at the TD Cowen 5th Annual Tools/Dx Revolution Conference in June 2026 revealed that 81% of surveyed investors expect multi-omics to become the standard of care or see broad adoption within five years. This transition is driven by three main factors: improving technology, decreasing costs, and the clinical evidence that integrating multiple biological layers delivers superior clinical performance.
AOA Dx is positioning its GlycoLocate discovery platform and AKRIVIS GD test to lead this space. By combining machine learning with lipidomic and protein profiling, the company aims to provide physicians with a blood-based signal that is more reliable than current options when patients first present with symptoms.
Pro Tip: Understanding Molecular Signatures
When evaluating new diagnostic technology, look for platforms that emphasize “coordinated signatures.” As noted by Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx, the most diagnostically informative signals are often found in the interactions between pathways rather than within any single one.
Frequently Asked Questions
What is the benefit of a multi-omic test for ovarian cancer?
Multi-omic tests analyze multiple biological layers—lipids, metabolites, and proteins—simultaneously. This provides a more comprehensive view of the disease, reducing the overlap often seen with traditional markers like CA125.
How does the AKRIVIS GD test work?
The test uses a combination of lipidomic profiling, protein immunoassay, and machine learning to identify coordinated molecular signatures in a patient’s blood sample.
Is multi-omics the future of cancer screening?
Industry data suggests a strong shift in this direction. According to the TD Cowen 5th Annual Tools/Dx Revolution Conference, 81% of surveyed investors believe multi-omics will reach broad adoption or become the standard of care within five years.
Are you interested in the intersection of artificial intelligence and early cancer detection? Subscribe to our newsletter for the latest updates on diagnostic breakthroughs or explore our archives on precision medicine to learn more about how molecular profiling is changing patient outcomes.
Worth a look